To include your compound in the COVID-19 Resource Center, submit it here.

Bourla chooses BD over buybacks in 2020

CEO Albert Bourla outlined his vision for the new innovative business that will emerge from Pfizer after the spin-off of Upjohn, saying that the company would invest in business development and pipeline growth rather than pursue buybacks in 2020.

“The past was a very different Pfizer. The past had to deal with declining revenues, constant declining revenues,” Bourla said on the company’s 2019 earnings call. “Now is a very

Read the full 684 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers